Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of “eye stroke” (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.
This article was originally published on MedicalXpress.com

